CARDIOACC
Developer of Cardiovascular Interventional Imaging Medical Devices
Medtronic
Medical Device Manufacturer
Strategic Cooperation Launch
Today, Medtronic Cardiac Ablation Solutions (CAS) Business Operations Department and Shenzhen CARDIOACC Technology Co., Ltd. officially signed a strategic cooperation agreement at the 8th China International Import Expo (CIIE). The two parties focused on CARDIOACC's independently developedIntracardiac Echocardiography Catheter (hereinafter referred to as "ICE")In mainland ChinaCommercialization and Therapy PromotionLaunch Long-term Strategic Cooperation, Jointly Promote the Popularization of ICE-guided Green Electrophysiology Ablation Therapy. Recently, Medtronic also completed a strategic investment in CARDIOACC, forming a multi-level strategic cooperation between the two parties.
Innovative Therapy ICE
"Visualizing" the Future of Precision Interventions
2025 CIIE
ICE（Intracardiac Echocardiography, Intracardiac Ultrasound) is an innovative technology in the field of cardiovascular interventionBy inserting a catheter integrated with a miniature ultrasound probe through the femoral artery into the cardiac chamber, high-definition and dynamic cardiac anatomical images are generated in real time, accurately displaying the cardiac chamber structure, lesion location, and adjacent relationships.
Compared with traditional X-ray imaging, ICE is green and radiation-free, better displays myocardial soft tissue structures, and reduces the need for intraoperative anesthesia. It provides precise navigation and real-time monitoring throughout various minimally invasive cardiac interventional procedures, allowing operators to "see more clearly and perform more steadily" during operations. This innovative technology not only significantly improves surgical success rates and shortens operation times but also effectively reduces the risk of postoperative complications and enhances patients' long-term prognosis. It brings good news to cardiovascular disease patients and leads cardiac interventional surgery into a new era of precision treatment.
Independent Innovation
China-Made ICE Products
2025 CIIE
CARDIOACC's self-developed AgileView intracardiac echocardiography imaging catheter was approved for Class III medical device registration in China in March 2025 (Registration No.: Z20253060489).The catheter has a diameter of only 7.5F.、It can effortlessly access the left heart system through the atrial septal puncture sheath, offering excellent reachability and flexible control. The product features an innovative self-locking handle design that enables one-hand bending adjustment and zero-position indication, significantly enhancing operational convenience and efficiency during procedures. Meanwhile, AgileView provides clear images with high resolution, andExclusive optimization for PFA (Pulsed Field Ablation) has been performed, enhancing bubble display and catheter contact performance, allowing operators to observe the energy delivery process more clearly and achieve truly visualized precision ablation.
Move Forward Together
Build an Integrated Electrophysiology Solution
2025 CIIE
Both parties share common areas of expertise in disease fields and a shared medical mission.CARDIOACC, focusing on innovative cardiac imaging technology; Medtronic, with its comprehensive training system and therapy ecosystem, jointly exerting efforts.Through this strategic cooperation, the two parties will achieve the deep integration of high-definition intraoperative imaging and precise ablation technology, providing doctors with a safer and more efficient surgical experience and patients with a more reassuring treatment process.
Signing Ceremony
In the photo, the guests in the front row from left to right are Mr. Adam Wang from Medtronic and Mr. Zhou Xinhuan from CARDIOACC; in the back row from left to right are Mr. Zhang Peitao from Medtronic, Mr. Lin Song, Mr. Laske Tim, Mr. Gu Yushao, and Rebecca.Mr. Ma Jun, Ms. Feng Wenhui, Ms. Ren Shuman, and Mr. Lin Wei from CARDIOACC.
Launch Ceremony
In the photo, the guests in the front row from left to right are Mr. Fu Cong from Medtronic, Mr. Zhang Peitao, Mr. Lin Song, Ms. Zhang Lei, Ms. Song Jingwei, Ms. Cao Shan, Mr. Laske Tim, Mr. Gu Yushao, Ms. Rebecca, Mr. Adam Wang, Mr. Zhou Xinhuan, Mr. Tarakji Khaldoun, Mr. Ma Jun, Mr. Wang Jinghua, Ms. Zhong Min, Mr. Zhou Quan, Ms. Wang Rong, Ms. Feng Wenhui, Mr. Lin Wei, and Ms. Ren Shuman.
Message
Rebecca SeidelMadam:
Medtronic Senior Vice President and Cardiac Ablation
Global President of Solution Operations Department
Medtronic has always believed that technological innovation can change the treatment landscape.The collaboration with CARDIOACC is an important step for us to promote local innovation and achieve global resource sharing.We look forward to promoting ICE therapy, allowing more Chinese patients to benefit from precise and visual interventional technology.
Gu YushaoMr.:
Medtronic Global Senior Vice President, Greater China President
Medtronic has reached a strategic cooperation and strategic investment with CARDIOACC，Build a multi-level cooperative pattern.In the future, Medtronic will continue to deeply connect with local innovative forces through diversified models such as commercial collaboration, strategic investment, and joint research and development, promoting the efficient alignment of global technology with China's actual needs.
Zhou XinhuanMr.:
CEO of CARDIOACC (Shenzhen) Co., Ltd.
This collaboration marks an important leap for domestically-produced ICE products from research and development to application.，It will also provide new possibilities for electrophysiology surgeries in China and even globally. CARDIOACC will adhere to the concept of "Innovation-driven, Patient-first" and move forward alongside Medtronic, promoting the popularization and optimization of green and precise electrophysiology surgeries.
Ma JunMr.:
Chief Operating Officer of CARDIOACC (Shenzhen) Technology Co., Ltd.
Being able to pass Medtronic's rigorous selection and achieve cooperation is both a gratitude for recognition and an invaluable淬炼for the company in terms of innovation, quality, and execution.We are honored to join hands with industry leaders, and will take this signing as a starting point to deepen collaboration in multiple fields, advance technology pragmatically, promote the progress of medical technology, and benefit patients.
Summary Remarks
Lin SongMr.:
Medtronic China's Cardiac Rhythm, Cardiac Surgery andCardiac AblationBusinessTeamVice President and China RegionCardiovascular Business PortfolioHead of Shared Functional Department
Today's signing is just the beginning. In the future, we will work hand in hand with CARDIOACC to bring high-quality medical innovations to more patients and make intracardiac ultrasound tools, which provide clear images and reduce radiation, a valuable assistant for clinicians.Thank you to both teams for their joint efforts. We look forward to working hand in hand to create more possibilities.
Company Profile
Medtronic
As a global leader in medical technology, Medtronic has always shouldered the mission of "alleviating pain, restoring health, and extending life," with its innovative medical technology covering more than 70 major disease areas.
In the field of cardiac electrophysiology, the Cardiac Ablation Solutions (CAS) business operations department of Medtronic China continues to drive innovation and the popularization of arrhythmia treatments — from cryoablation to radiofrequency ablation, and now to the world's first PFA pulse ablation catheter approved by the FDA. It is committed to providing Chinese doctors with advanced therapeutic tools and bringing Chinese patients a more reassuring, comfortable, and efficient treatment experience.
Shenzhen CARDIOACC Technology Co., Ltd.
Founded in October 2021, CARDIOACC is dedicated to the research and development of innovative medical devices for cardiac interventional imaging, aiming to create high-end medical imaging products with global competitiveness. CARDIOACC has established a robust technological barrier by deploying multiple patents both in China and overseas. Its two-dimensional intracardiac echocardiography (ICE) leads the industry in various imaging metrics. Additionally, the four-dimensional ICE independently developed by CARDIOACC utilizes a volumetric scanning imaging solution based on soft beam synthesis, avoiding the use of massive array elements and complex ASIC chips, while offering a large field of view and high volume rate, achieving real-time 3D imaging while maintaining image quality.
